Clinical Trials Browser

Recurrence × trametinib × Plasma cell × Clear all

NCT02140840 2016-04-07

UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib

Phase 2 Withdrawn

Multiple Myeloma, Recurrence